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Abstract Although functional neurological symptoms
are often very disabling there is limited information on
outcome after treatment. Here we prospectively assessed
the short- and long-term efficacy of an inpatient multidis-
ciplinary programme for patients with FNS. We also
sought to determine predictors of good outcome by
assessing the responsiveness of different scales adminis-
tered at admission, discharge and follow-up. Sixty-six
consecutive patients were included. Assessments at
admission, discharge and at 1 year follow-up (55 %)
included: the Health of the Nation Outcome Scale, the
Hospital Anxiety and Depression Scale, the Patient Health
Questionnaire-15, the Revised Illness Perception Ques-
tionnaire, the Common Neurological Symptom Question-
naire, the Fear Questionnaire and the Canadian
Occupational Performance Measure. At discharge and at
1 year follow-up patients were also asked to complete five-
point self-rated scales of improvement. There were sig-
nificant improvements in clinician-rated mental health and
functional ability. In addition, patients reported that their
levels of mood and anxiety had improved and that they
were less bothered by somatic symptoms in general and
neurological symptoms in particular. Two-thirds of patients
rated their general health such as ‘‘better’’ or ‘‘much bet-
ter’’ at discharge and this improvement was maintained
over the following year. Change in HoNOS score was the
only measure that successfully predicted patient-rated
improvement. Our data suggest that a specialized multi-
disciplinary inpatient programme for FNS can provide
long-lasting benefits in the majority of patients. Good
outcome at discharge was exclusively predicted by
improvement in the HoNOS which continued to improve
over the 1 year following discharge.
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Introduction
Functional neurological symptoms (FNS) represent one of
the commonest diagnoses made in outpatient neurology
clinics [1]. Long-term follow-up studies report lack of
recovery and even worsening of symptoms in one half to
two-thirds of patients [2, 3].
To date there are no official guidelines for the treatment
of FNS. Different approaches, including pharmacotherapy
(mainly antidepressants) [4], psychological therapies (both
cognitive-behavioural and psychodynamic) [5, 6], hypno-
therapy [7] and physical rehabilitation [8, 9], have been
considered helpful in a variable proportion of patients with
FNS. Inpatient treatment programmes combining different
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approaches [10, 11] have also been described. We have
recently shown that patients with functional symptoms [11]
benefitted from this approach; but the sample was small,
and only included patients with functional motor symptoms.
In addition, this a retrospective study, based on patients’
own estimation of their disability up to 7 years earlier. In
another study, also restricted to functional motor symptoms,
McCormack et al. found significant improvement following
a multidisciplinary inpatient programme. This was again
retrospective and relied on case notes rather than direct
patient contact [12]. Recently, Jordbru et al. [13] examined
the effect of a 3 week inpatient rehabilitation programme on
60 patients affected by functional gait disorders; they found
patients to significantly improve their ability to walk and
their quality of life after inpatient rehabilitation compared
with the untreated control group. This was the first ran-
domized controlled trial assessing inpatient programme for
FNS. Nevertheless, the focus of the programme was phys-
ical rehabilitation; occupational therapy and cognitive-
behavioural therapy were not provided. In addition, they
only included in the study patients with functional gait
disorders.
In this study, we examined prospectively the short- and
long-term efficacy of an inpatient multidisciplinary pro-
gramme for patients with functional neurological symp-
toms of all types. To do this we used a range of clinician-
and patient-rated assessment scales to measure mental
health, physical symptoms, every-day function and illness
perception. We additionally evaluated the responsiveness
of these instruments to patients’ own self-report of change




Sixty-six consecutive patients affected by functional neu-
rological symptoms (FNS) treated within a specialized
multidisciplinary inpatient programme between January
2010 and May 2012 was included. This was a different
patient group to that described in our previous study [11]. All
patients were older than 18 years and were able to commu-
nicate well in written and spoken English. Ethical approval
was obtained from the UCL Institute of Neurology and
National Hospital for Neurology Joint Ethics Committee and
all patients provided written informed consent to participate.
Description of the programme
Patients were admitted to the neuropsychiatry inpatient unit
of The National Hospital for Neurology and Neurosurgery,
Queen Square, London for a 4 week treatment programme.
All the patients who accepted programme have an estab-
lished diagnosis of functional neurological symptoms which
has been ascertained by a neurologist and psychiatrist on the
basis of clinical presentation and appropriate investigations.
To optimize the efficacy of the programme, a few months
before the admission patients attend an assessment clinic
where they have the opportunity to meet the multidisci-
plinary team and discuss their diagnosis and the rationale
behind the programme. On admission, the treatment plan is
individualized and tailored to each patient according to his or
her treatment goals. Common features are cognitive-
behavioural therapy, occupational therapy, physiotherapy,
neuropsychiatry and neurology assessment and input. For
further details on the programme please see Saifee et al. [11].
Assessment
Self-report and clinician-rated assessments were completed
by the patients at admission and discharge. At 1 year fol-
low-up, all patients were sent the self-report questionnaires
and a psychiatrist conducted a telephone assessment using
a semi-structured interview for the clinician-rated scales.
Clinician-rated assessments
Health of the Nation Outcome Scale (HoNOS)
This is a well-validated 12-item instrument for the
assessment of psychiatric symptoms, behaviour, impair-
ment and social functioning in patients with mental ill-
nesses. It is the most widely clinician-rated routine
outcome measure in British mental health services [14].
Each category is scored on a scale ranging from 0 to 4:
0 = no problem; 1 = minor problem requiring no action;
2 = mild problem but definitely present; 3 = moderately
severe problem; 4 = severe to very severe problem. A
higher score therefore indicates greater impairment, and
the maximum score is 48.
Canadian Occupational Performance Measure (COPM)
This is an individualized measure designed for use by
occupational therapists to detect change in a patient’s self-
perception of occupational performance over time; it is
administered via semi-structured interview. This measure is
used to help patients identify areas of difficulty in self-care,
productivity, and leisure. Following identification of up to
five problem areas, patients rate each on a scale from 1
(least important) to 10 (most important). Patients also rate
their current level of performance and satisfaction with their
performance in each of the five areas on a scale from 1 (with
great difficulty or not satisfied) to 10 (with no difficulties or
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completely satisfied). On re-assessment, patients review
their goals and again rate their performance and satisfaction
on the goals identified in the initial assessment [15]. The
COPM has been shown to be a valid measure of functional
outcomes and is sensitive to change. An improvement of
two points is regarded as clinically significant [16].
Self-report assessments
Hospital Anxiety and Depression Scale (HADS)
This is a reliable 14-item self-assessment scale developed to
detect states of anxiety, depression and emotional distress
among patients who were treated for several medical con-
ditions [17]. The items are scored on a 4-point Likert scale,
ranging from 0 to 3: score range is 0–42 for the total score.
Fear Questionnaire (FQ)
This is a brief 15-item self-report measure of three
dimensions of fear (agoraphobia, social phobia, and blood/
injury phobia). The FQ is a frequently used measure in
anxiety disorder assessment and research and has been used
to measure fear in a variety of other clinical populations
[18]. The score range is 0–150; higher scores indicate
greater agoraphobia, social phobia, and blood/injury
phobia.
Patient Heath Questionnaire-15 (PHQ-15)
This is a multiple-choice self-report inventory, used as a
screening and diagnostic tool for somatic symptoms. It was
designed for use in the primary care setting but it is now
commonly used in specialized settings [19]. The symptoms
inquired include 14 of the 15 most prevalent somatic
symptoms listed in the Diagnostic and Statistical Manual of
Mental Disorders-fifth edition (DSM-V) criteria for
somatization disorder [20]. Each individual symptom is
coded as 0 (not bothered at all by this symptom), 1 (slightly
bothered by this symptom), or 2 (bothered a lot by this
symptom), and the total score ranges from 0 to 30. Higher
scores represent worse somatic symptoms.
The Common Neurological Symptom Questionnaire
(CNSQ)
This is a nine item questionnaire where patients are asked
to indicate in the last 4 weeks how bothered have they have
been (not at all bothered, slightly bothered, bothered a lot)
by a range of common neurological symptoms [21]. Each
individual symptom is coded as 0, 1, or 2 as for the PHQ-
15, and the total score ranges from 0 to 27 with higher
scores meaning more bothered.
The Revised Illness Perception Questionnaire (IPQ-R)
This is a reliable and well-validated self-report instrument
for assessing cognitive representations of illness. It is a
theoretically derived measure comprising sub-scales that
provides information about the components that have been
found to underlie the cognitive representation of illness.
These are: timeline acute/chronic—the belief about the
chronicity of illness, consequence—the expected adverse
effects and outcomes; timeline cyclical—the day to day
variability of symptoms; personal control—the degree to
which symptoms can be self-controlled; treatment con-
trol—the degree to which symptoms can be helped with
treatment; illness coherence—understanding about symp-
toms; emotional representations—degree of distress caused
by symptoms. Each question is answered on a 1–5 Likert
scale, and subscores for each of domain are calculated [22].
Following the methodology of Sharpe et [21], self-
assessment of outcome at discharge and 1 year follow-up
was established by asking patients to complete a five-point
scale (CGI), which asked them to compare their current
general health with that before the admission on a five-
point scale (‘‘much worse’’; ‘‘worse’’; ‘‘not changed’’;
‘‘better’’; ‘‘much better’’). They were also asked to make
the same rating for improvement specifically in their pre-
senting symptoms (IPS).
Analysis
Statistical analysis was performed using SPSS version 21
(Statistical Package for Social Science). First, we com-
pared the sample of patients on whom we had 1 year fol-
low-up data with the sample of patients on whom these
data were missing, using t test and v2 test as appropriate, to
test whether we had an inclusion bias. We then compared
outcomes on the CGI and IPS scales administered at dis-
charge and at 1 year follow-up using the Friedman test.
The CGI score was used to define two groups: good out-
come (CGI: ‘‘much better’’ or ‘‘better’’) and poor outcome
(CGI: ‘‘not changed’’, ‘‘worse’’, ‘‘much worse’’). Differ-
ences in the mean scores of each scale were assessed using
repeated measures ANOVA over the following time points:
on admission, on discharge and at 1 year follow-up. Cor-
relation analyses were undertaken using Pearson or
Spearman’s correlation coefficient as appropriate.
Results
Sixty-six patients were assessed at admission and discharge.
The median age was 43.7 years (SD 14.7) and 70.2 % were
females. The dominant symptoms on admission were
movement disorders (50.5; 16.1 % dystonia, 8.9 % jerks,
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8 % tremor, gait disturbances 7.5 % and 10 % mixed),
psychogenic non-epileptic seizures (21.2 %), weakness
(18.8 %) and sensory symptoms (9.5 %). The mean illness
duration was 4.8 years (DS 3.2 years, range 1–8 years).
At the time of admission, 33 % of patients had a
comorbid mood disorder (mainly depression), 39 % an
anxiety disorder; 16 % had a diagnosis of personality dis-
orders. None of the patients had a diagnosis of psychosis.
At the time of admission, 71 % of patients had left their
job because of illness, and 95 % were in receipt of health-
related financial benefits.
Symptoms
Table 1 shows that for the group as a whole there were
significant improvements in: HoNOS, HADS, PHQ15, and
CNSQ. The effect sizes were large for HoNOS, medium for
PHQ and CNSQ and small for HADS.
At discharge 66.2 % patients rated their general health
such as ‘‘better’’ or ‘‘much better’’ on the CGI and 75.0 %
rated their main symptoms as ‘‘better’’ or ‘‘much better’’ on
the IPS (Fig. 1). A binary logistic regression analysis was
conducted to examine whether the variables that improved
with treatment predicted, at baseline, the self-rated out-
come on the CGI. The combination of variables classified
correctly 70.5 % of patients. The overall model was not
significant (v2 = 2.18, df = 4, p = 0.70) and only 4.9 %
of the variance in outcome could be explained (Nagelkerke
R2). This was repeated for change scores of the same
variables. The classification was improved (75 %), the
model fit was significant (v2 = 9.62, df = 4, p = 0.047)
and 20.8 % of the variance in outcome was explained. Of
the four variables entered, only change in HoNOS score
was a significant predictor of self-rated outcome (Wald
(1) = 4.52, p = 0.033).
Function
The Canadian occupational performance measure (COPM),
a measure of self-perceived change, was completed on 51
patients. There was a mean improvement of 3.12 (1.78)
points for performance and 3.90 (2.06) points for satis-
faction between baseline and discharge for the whole
group. Change in neither performance nor satisfaction
subscales predicted self-rated improvement on CGI (model
fit: v2 = 5.30, df = 2, p = 0.07; performance: Wald
(1) = 1.50, NS; satisfaction: Wald (1) = 0.02, NS).
Illness perception
For the whole group, there were significant changes
between admission and discharge on the IPQR timeline
Table 1 Group mean (standard deviation) changes in assessment scores between admission and discharge
N Admission Discharge t statistic Effect size
(Cohen’s d)
HoNOSa 64 9.7 (4.1) 6.4 (3.9) 10.0 p \ 0.001 0.84
HADSb 62 15.8 (8.5) 13.3 (8.2) 3.0 p = 0.004 0.26
FEARc 66 35.1 (26.9) 31.3 (26.8) 1.8 p = 0.07 0.14
PHQ15d 64 12.6 (5.5) 9.8 (5.1) 5.4 p \ 0.001 0.53
CNSQe 64 8.0 (4.3) 6.0 (3.8) 4.1 p \ 0.001 0.50
IPQ-R timeline acute/chronicf 61 18.4 (4.4) 16.2 (4.4) 4.5 p \ 0.001 0.51
IPQ-R timeline cyclicalf 61 13.4 (3.9) 13.3 (4.2) 0.1 p = 0.90 0.02
IPQ-R consequencesf 61 22.7 (4.9) 21.5 (4.4) 2.4 p = 0.02 0.26
IPQ-R personal controlf 61 21.5 (3.6) 22.5 (4.1) 1.8 p = 0.07 0.27
IPQ-R treatment controlf 61 18.4 (2.9) 17.7 (4.6) 1.1 p = 0.25 0.18
IPQ-R illness coherencef 61 13.5 (5.0) 17.5 (4.6) 5.6 p \ 0.001 0.84
IPQ-R emotional representationf 61 20.5 (5.6) 18.7 (5.5) 2.7 p = 0.009 0.32
HoNOS Health of the Nation Outcome Scale; HADS Hospital Anxiety and Depression Scale; FEAR Fear Questionnaire; PHQ-15 Patient Heath
Questionnaire-15; CNSQ Common Neurological Symptom Questionnaire; IPQ-R Revised Illness Perception Questionnaire
a Score range = 0–48. Higher score indicates greater impairment
b Score range = 0–42. Higher score indicates grater anxiety and depression
c Score range = 0–150. Higher scores indicate greater agoraphobia, social phobia, and blood/injury phobia
d Score range = 0–30. Higher scores represent worse somatic symptoms
e Score range = 0–27. Higher scores indicate more bothered by common neurological symptoms
f Score range = 0–30. Higher scores indicate stronger perception of illness chronicity, a cyclical timeframe and negative consequences, and
greater emotional distress; lower scores indicate low perceived personal and treatment control over the illness and less understanding of the
illness. The IPQ-R scoring information are available online (www.uib.no/ipq)
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acute/chronic; illness coherence; emotional representations
and consequences subscales. Binary logistic regression
analyses for the admission scores on CGI outcome showed
that 69 % of the patients were classified correctly, the
overall model was not significant (v2 = 1.81, df = 4,
p = 0.77) and only 3.8 % of the variance could be
explained (Nagelkerke R2). Similarly, when change scores
were entered, 67 % patients were correctly classified, the
overall model was not significant (v2 = 6.52, df = 4,
p = 0.16) and 14 % of variance was explained.
Long-term outcome
Thirty-six (55 %) patients returned their questionnaires and
were interviewed by telephone approximately, 12 months
after discharge (range: 10-15 months). At discharge,
72.2 % rated their general health as ‘‘better’’ or ‘‘much
better’’ on the CGI and 80.5 % rated their main symptoms
as ‘‘better’’ or ‘‘much better’’ on the IPS. At 12 months,
these figures were 66.6 and 63.9 %. We compared how the
CGI and IPS self-rating had changed from discharge to
follow-up; 13.9 and 25 %, respectively rated themselves
better at discharge but unchanged at follow-up; 8.3 and
8.3 %, respectively rated themselves as unchanged at dis-
charge and better at follow-up.
Compared to those who did not complete the 12 month
assessment, the patients who were followed up at
12 months had lower scores on the HoNOS (t(62) = 2.22,
p = 0.030 and the FEAR questionnaire (t(64) = 3.32,
p = 0.001) at admission; they also rated their symptom
fluctuations as having a less deleterious impact (IPQ
timeline cyclical t(63) = 3.33; p = 0.001).
Table 2 shows repeated measures analyses of variance
over the three time points (admission, discharge and
12 months follow-up). A significant time course effect was
found for: HoNOS, PHQ15, CNSQ and several subscales
of the IPQ (timeline acute/chronic, illness coherence,
emotional representation). There was a strong trend for a
significant time course effect for HADS. For these vari-
ables, pairwise contrasts between admission and discharge
scores showed significant improvements in all of these
variables. Pairwise contrasts between discharge and
12 months were significant for improvement in HoNOS
(t(30) = 3.24; p = 0.003; d = 0.69) and deterioration in
timeline acute/chronic IPQR subscale (t(33) = 2.83,
p = 0.008; d = 0.61).
The COPM was completed on 27 patients at 12 months
follow-up. These patients showed an improvement from
admission of 3.30 (2.59) for performance and 4.12 (2.72)
for satisfaction. When changes between admission and
discharge were compared with discharge and 12 months
there were no differences (performance: t(34) = 0.58; sat-
isfaction: t(34) = 0.58). Illness perceptions for the group
that was followed up showed a change from admission for
illness coherence (t(32) = -4.64; p B 0.001) and emo-
tional representation (t(32) = 2.24; p = 0.032).
Discussion
We studied a large group of patients with functional neu-
rological symptoms who were consecutive admissions for a
4 week multidisciplinary treatment programme. We found
significant improvements in clinician-rated mental health
and functional ability. In addition, patients reported that
their levels of mood and anxiety had improved and that
they were less bothered by somatic symptoms in general
and neurological symptoms in particular.
The effect size for these improvements was greatest for
the HoNOS. The HoNOS is a clinician-rated scale devised
Fig. 1 Patient-rated outcome at discharge and at 1 year follow-up on
CGI and IPS Likert scales. CGI clinical global improvement; IPS
improvement in presenting symptom. At discharge 2.8 % patients
rated their general health such as ‘‘much worse’’, 2.8 % such as
‘‘worse’’, 22.2 % such as ‘‘no change’’, 47.2 % such as ‘‘better’’,
25 % such as ‘‘much better’’ on the CGI and 2.8 % rated their main
symptoms such as ‘‘much worse’’, 5,5 % such as ‘‘worse’’, 16.7 %
such as ‘‘no change’’, 72.8 % such as ‘‘better’’ and 2.2 % such as
‘‘much better’’ on the IPS. At 1 year follow-up 5.6 % patients rated
their general health such as ‘‘much worse’’, 11.1 % such as ‘‘worse’’,
16.7 % such as ‘‘no change’’, 44.4 % such as ‘‘better’’, 22.2 % such
as ‘‘much better’’ on the CGI and 5.6 % rated their main symptoms
such as ‘‘much worse’’, 8.3 % such as ‘‘worse’’, 22.2 % such as ‘‘no
change’’, 38.9 % such as ‘‘better’’ and 25 % such as ‘‘much better’’ on
the IPS
2374 J Neurol (2014) 261:2370–2377
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to assess outcome in people with mental illness and
incorporates brief assessments of mental health, social
function and behaviour [14]. It is used routinely in the UK,
New Zealand and Australia and increasingly so in other
European countries and Canada. A comprehensive review
[23] concluded that the psychometric properties of the
HoNOS are ‘adequate or better’ indicating that it can be
used for monitoring outcomes following treatment. Patients
with functional symptoms are prone to many aspects of
disability captured by the HoNOS, e.g. mood, cognitive
and functional impairments. Our study suggests that the
HoNOS is a suitable instrument for detecting meaningful
improvement following treatment for functional neurolog-
ical symptoms.
The HoNOS, being a clinician rated scale, does not take
into account the patient perspective. We therefore, asked
patients to rate their outcome using the CGI which asks
them to state whether they are ‘‘much worse’’; ‘‘worse’’;
‘‘not changed’’; ‘‘better‘‘; ‘‘much better’’. We then
classified patients as improved if they rated themselves as
‘‘much better’’ or ‘‘better. Sixty-six percent of patients
were classified as improved using this scheme. The change
on HoNOS rating following treatment was the only
assessment scale able to predict with reasonable accuracy
those who rated themselves as improved and not improved
at discharge from hospital. This suggests that the HoNOS
tallies well with the patients’ own opinion of their response
to treatment, a further validation of the use of the scale for
assessing outcomes.
Self-reported improvements in mood and anxiety mea-
sured by the HADS and the degree of distress over
symptoms measured by PHQ and CSNQ did not predict
whether the patients felt they were better or not at the end
of treatment. There were significant improvements in these
measures across the group but the effect sizes were small to
medium suggesting that these measures were not sensitive
enough to self-perceived change. The COPM scores also
failed to predict whether patients felt they were better or
Table 2 Repeated measures analyses of variance over the three time points (admission, discharge and 12 months follow-up)






HoNOS 8.7 5.6 4.0 F(2,30) = 32.42
p \ 0.001
0.52 (a) t(35) = 7.6; p \ 0.001
(b) t(30) = 3.2; p = 0.003
HADS 14.3 11.3 12.6 F(2,35) = 2.75
p = 0.07
0.07 (a) t(35) = 2.7; p = 0.011
(b) NS
FEAR 25.8 (15.5) 24.9 (19.0) 27.4 (20.9) F(2,35) = 0.43
p = 0.65
0.01
PHQ15 11.7 9.2 9.2 F(2,35) = 5.21
p = 0.001
0.13 (a) t(35) = 3.9; p \ 0.001
(b)NS
CNSQ 7.5 5.4 5.7 F(2,35) = 5.20
p = 0.008




18.8 16.7 19.4 F(2,32) = 4.66
p = 0.01
0.13 (a) t(34) = 3.0; p = 0.005
(b) t(30) = -2.8; p = 0.008
IPQ-R timeline cyclical 11.9 12.9 12.8 F(29) = 0.63
p = 0.54
0.02
IPQ-R consequences 23.2 22.2 21.6 F(2,29) = 1.35
p = 0.27
0.04
IPQ-R personal control 21.5 23.4 21.5 F(2,29) = 1.89
p = 0.16
0.06
IPQ-R treatment control 18.4 18.0 17.8 F(2,29) = 0.32
p = 0.73
0.01
IPQ-R illness coherence 13.4 17.88 17.0 F(2,29) = 13.32
p \ 0.001
0.32 (a) t(31) = 4.4 p \ 0.001
(b) NS
IPQ-R emotional representation 20.6 18.79 17.8 F(2,29) = 3.65
p = 0.03
0.11 (a) t(31) = 2.1; p = 0.044
(b) NS
HoNOS Health of the Nation Outcome Scale, HADS Hospital Anxiety and Depression Scale, FEAR Fear Questionnaire, PHQ-15 Patient Heath
Questionnaire-15, CNSQ Common Neurological Symptom Questionnaire, IPQ-R Revised Illness Perception Questionnaire
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not. This is a clinician-guided scale enabling patient to set
goals and rate their change in performance and their sat-
isfaction. As a change in 2 points is regarded as clinically
meaningful, our patient group clearly benefitted from the
treatment as they reported a mean of 3 and 4-point change
in performance and satisfaction, respectively. Similarly,
there were significant changes in the perception of their
symptoms following treatment; overall patients understood
their symptoms better and felt they were less permanent
and disabling. Again these changes did not predict whether
they felt better or not.
Just over 50 % of patients were reassessed 12 months
after discharge. Despite these patients having lower Ho-
NOS scores at admission, compared to the group that were
not followed-up, their pattern of improvement at discharge
from the treatment programme was virtually identical to
the group as a whole. These improvements remained stable
over the 12 months following discharge for all self-rated
measures, and their HoNOS scores continued to improve.
These data are consistent with the results of retrospective
studies of functional movement disorders. For example,
Saifee et al. in a different smaller population of patients who
completed our programme between 2006 and 2008 [11],
and Williams et al. [24], assessing a different hospital based
programme, found that functional motor symptoms
improved in the majority of patients. Our study extends
these results by employing a more accurate prospective
design, examining long-term outcome by directly contact-
ing the patients 12 months after discharge, and including
patients with a range of functional neurological symptoms.
Previous studies have shown that treatments used for
FNS, such as cognitive-behavioural therapy [5, 6] or medi-
cations [4], often provide an initial improvement in symp-
toms but benefits are not maintained in the long-term. In fact,
it has been widely described that patients with FNS have a
high frequency of relapse or chronicity of the symptoms [25,
26]. Our study suggests that a multidisciplinary approach is
important for sustained long-term improvement.
A significant problem for the management of functional
neurological symptoms in the UK is that local services are
usually unable to accept patients for initial or post-dis-
charge continuing treatment because of the level of demand
for their service from neurological patients with organic
disorders. An MDT service such as ours is labour-intensive
and therefore expensive. Ideally, to optimize the effec-
tiveness of an MDT provision, patients who are likely to
benefit from MDT therapy should be identified as early as
possible in the care pathway. This is underlined by the
finding by Jordbru et al. [13] that physiotherapy-based
rehabilitation alone may be effective for some. Unfortu-
nately, none of measures we used at baseline, including the
HoNOS, predicted response to treatment as perceived by
patients. Our current data therefore suggests that none of
these measures could be used to identify which patients are
likely to benefit. Alternatively, our measure of patient
satisfaction may have been too crude and a dimensional
scale such as the CORE-OM may be a better self-assess-
ment tool. This has been validated for patients undergoing
therapy and has the advantage of capturing several domains
at once including well-being, symptoms and functioning.
Limitations
We acknowledge the limitations of our study: first, we
only achieved 1 year follow-up data on 55 % of patients.
Second, there are other potential predictors of good or
poor outcome that we did not measure [2]; these might be
social such as the receipt of health-related financial ben-
efit and the work situation, or psychological such as the
presence of dissociative symptoms and the presence of
alexithymia (two aetiological markers of FNS) [27, 28].
Third, the absence of a control group makes it difficult to
know to what extent the improvement observed in our
patients represented a specific response to treatment
intervention.
Conclusions
Our data suggest that a specialized multidisciplinary
inpatient programme for FNS can provide long-lasting
benefits in the majority of patients. Good outcome at dis-
charge, as rated by the patient, was only predicted by
improvement in the HoNOS which continued to improve
over the 1 year following discharge. The HoNOS appears
to be a suitable tool for the detection of meaningful
improvement following multidisciplinary treatment.
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